BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33057841)

  • 1. Economic perspective of cancer treatment in India.
    Natarajan A; Mehra N; Rajkumar T
    Med Oncol; 2020 Oct; 37(11):101. PubMed ID: 33057841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of generic medicines and biosimilars in oncology in low-income countries.
    Renner L; Nkansah FA; Dodoo AN
    Ann Oncol; 2013 Sep; 24 Suppl 5():v29-32. PubMed ID: 23975702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
    Bennett CL; Sartor OA; Armitage JO; Kantarjian H
    Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
    [No Abstract]   [Full Text] [Related]  

  • 4. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
    American Society of Clinical Oncology
    J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
    [No Abstract]   [Full Text] [Related]  

  • 5. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
    Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
    J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generics and Biosimilars: Barriers and Opportunities.
    Scheckel CJ; Rajkumar SV
    Mayo Clin Proc; 2021 Dec; 96(12):2947-2957. PubMed ID: 34728057
    [No Abstract]   [Full Text] [Related]  

  • 7. A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.
    Wehrwein P
    Manag Care; 2019 Jan; 28(1):12-15. PubMed ID: 30883317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing oncology biosimilars: an essential approach for the future.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
    Mellstedt H
    Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Heart Association Principles on the Accessibility and Affordability of Drugs and Biologics: A Presidential Advisory From the American Heart Association.
    Antman EM; Creager MA; Houser SR; Warner JJ; Konig M;
    Circulation; 2017 Dec; 136(24):e441-e447. PubMed ID: 29122813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.
    Henry D; Taylor C
    Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do biosimilars sustain value, affordability, and access to oncology care?
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):327-329. PubMed ID: 32842809
    [No Abstract]   [Full Text] [Related]  

  • 13. [Can we transfer the mechanisms of the generics market to biosimilars?].
    Jacke CO; Wild F
    Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empower physicians to fight financial toxicity with biosimilars.
    Oubre K
    Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP374-SP375. PubMed ID: 31860250
    [No Abstract]   [Full Text] [Related]  

  • 15. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN.
    Dolinar R; Lavernia F; Edelman S
    Endocr Pract; 2018 Feb; 24(2):195-204. PubMed ID: 29466056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory and clinical considerations for biosimilar oncology drugs.
    Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
    Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The development of biosimilars in oncology].
    Jiang SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.
    Sathyanarayanan V; Flowers CR; Iyer SP
    JCO Glob Oncol; 2020 Jul; 6():1124-1133. PubMed ID: 32692628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in the Caribbean--key considerations.
    Cox SD
    West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
    [No Abstract]   [Full Text] [Related]  

  • 20. Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary).
    Cross G
    Drugs Today (Barc); 2018 Aug; 54(8):499-505. PubMed ID: 30209444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.